INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HSCT) is a potentially curative therapy for several hematologic diseases. GvHD is a major complication affecting an ever increasing number of long-term survivors. [1] [2] [3] [4] GvHD arises when donor T-cells act against the cells of the immunocompromised host recipient because of histocompatibility antigen disparity. 2 The chronic form of GvHD (cGvHD) may be lethal and survivors have to face the challenge of severe morbidity, which considerably impairs their quality of life (QoL), particularly those domains related to physical function (see below). Moreover, prolonged cGvHD is a risk factor for other complications 5 and a prognostic factor for overall survival and relapse-free survival. 6 Systemic corticosteroid therapy is the standard first-line treatment for cGvHD, although under 40-50% respond favorably and secondary and tertiary treatments have been associated with a high rate of failure. 7 In view of these poor treatment outcomes and the toxic effects of treatment, a main research objective is to identify new treatment strategies that will help preserve or even improve the QoL of these patients. Such strategies should specifically target the physical domain of QoL, thus minimizing impacts on daily living activities. It is widely known that an active lifestyle has numerous beneficial effects on the course of most chronic diseases ultimately improving patient well being. 8 It is therefore no surprise that physical exercise is often recommended as a therapeutic tool for numerous conditions, although its effects on patients with cGvHD are largely unknown. Work in this field requires valid reliable tools to accurately define the physical condition of a patient and the patient's response to a given intervention in terms of effects on daily living activities. This brief review provides an overview of our current understanding of this debilitating disease, how it affects the patients' functional capacity and physical domain of QoL and what can we can learn from preclinical exercise intervention studies. Recommendations are also given for future exercise studies in patients targeting mainly to improve their physical function and physical function-related domains of QoL.
SUMMARY OF DIAGNOSIS CRITERIA FOR CGVHD
The National Institutes of Health (NIH) Consensus Working Group for Diagnosis and Staging of cGvHD considered the clinical and pathological characteristics of GvHD [9] [10] [11] [12] [13] [14] to define two main categories each with two subcategories (Figure 1 ): acute GvHD (aGvHD), including classic aGvHD and late-onset aGvHD; and cGvHD, comprising classic cGvHD and overlap syndrome. 9 Overlap syndrome is characterized by a poor prognosis, functional impairment and higher symptom burden and mortality. 15 The NIH also consider the necessary clinical manifestations for a diagnosis of cGvHD (Table 1 ) distinguishing this form from aGvHD when there is at least one diagnostic clinical sign of cGvHD or at least one distinctive manifestation confirmed by biopsy or other relevant tests, along with the exclusion of other possible diagnoses. 9, 16 SUMMARY OF THE PATHOBIOLOGY OF CGVHD The events leading to the development of cGvHD have been defined in large measure using murine models that show three disease mechanisms: (i) the production of auto-antibodies (typically 1 anti-DNA); (ii) the development of fibrosis; and (iii) abnormal thymus function. [17] [18] [19] Since none of these events per se faithfully reproduces the mechanisms of human cGvHD, 17, 18 two other new models have appeared: one recapitulating a transition from aGvHD to a scleroderma-like form of cGvHD with salivary gland involvement and serum antibodies, 20 and another reproducing a systemic disease with multi-organ involvement, in which lung and liver fibrosis are associated with CD4 + T-cell and B-cell infiltration. + T-cells, with CD4 + and CD8 + cell infiltrates detected in oral lichenoid lesions, 22 and CD8 + infiltrates detected in the skin, intestine and oral mucosa. 23, 24 The expression of CD134 (OX40) on the surface of CD8 + and CD4 + T-cells has been associated with cGvHD onset, and marks an early T-cell activation by inflammatory cytokines. 25 A decline in regulatory T-cells (T regs ) leads to a loss of peripheral tolerance, autoimmunity and cGvHD. 19, 26 In fact, patients with cGvHD have lower numbers of CD4 + T regs compared with patients without cGvHD. 27, 28 The role played by B lymphocytes in cGvHD has been well established, [29] [30] [31] [32] [33] with patients showing high levels of B-cell activating factor. 31, [33] [34] [35] [36] [37] [38] There could be an increased B-cell activating factor/B-cell ratio resulting in an immune pathology. 31, 33, 36 The development of cGvHD is also related to an increase in B-cells expressing high levels of the toll-like receptor 9. 38 In addition, given that many memory B-cells express auto-reactive antibodies, the inflammation present during GvHD activates these cells to produce allo/auto-antibodies. 21, [39] [40] [41] Further, an immune system recovery process poor in B-cells leads to a state of immunodeficiency increasing the risk of infection. 21, 29, 33, 37 Finally, the decrease produced in naive and transition B-cells increases the auto-reactivity of B-cells with antigenic experience (expressing CD27 + ). 33 This subgroup of B-cells circulates in patients with cGvHD who present B-cell activating factor receptors. 33 The damage caused by conditioning regimens in the thymus, previous aGvHD, atrophy and/or the prophylactic regimen, deregulates central tolerance mechanisms during the immune recovery that leads to cGvHD. 42 Regarding fibrotic changes, several complement factors have a role in cGvHD. Complement factor 3 is deposited at the dermis-epidermis junction and complement factor 5 modifies liver fibrosis. 43 Chemokines C-C motif ligand-3 and 2 are chemotactic for mononuclear phagocytes and are essential pro-fibrotic mediators. 44 T-CD4 + lymphocytes are stimulated by class II antigenic determinants expressed on fibroblasts, keratinocytes and other cells, and once activated, these cells produce cytokines (IL4, transforming growth factor (TGF)β) that induce collagen production by the fibroblasts, thereby producing fibrotic lesions in the skin, liver, exocrine glands and thymus which are characteristic of cGvHD. 45 Specifically, TGFβ is involved in autoimmune diseases and cGvHD. 46 
CLINICAL MANIFESTATIONS OF CGVHD: IMPLICATIONS FOR PATIENTS' PHYSICAL FUNCTION AND QOL
The clinical manifestations of cGvHD resemble those observed in an autoimmune disease such as systemic lupus erythematosus, lichen planus and scleroderma, 2, 9, 16, 40, 47, 48 affecting a single organ or many body zones. 9 Initial signs usually appear in the oral mucosa with other organs involved such as the skin, nails, eyes, muscles, lungs, tendons, gastrointestinal tract, liver, joints, nerves, kidneys, serous membranes, genitals, heart and immune system (see Figure 2) . Thus, this disease has a negative impact on the chain of interactive events involved in physical exercise capacity, mainly blood oxygenation (which depends on pulmonary function), supply of oxygenated blood to the working muscles (which depends on the cardiac pump) and muscle function.
QoL is a multi-dimensional concept describing patients' perceptions of the impacts of their disease and its treatment on their physical, psychological, social, financial and spiritual well-being. [49] [50] [51] Chronic GvHD has a negative impact on QoL, 1, 15, 48, 50, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] although this is not detectable in all patients. 69 According to the NIH criteria for grading cGvHD severity, patients with mild cGvHD have higher QoL than those with moderate aGVHD Classic aGVHD.
Manifestations occurring before day 100. Absence of cGVHD features.
Persistent, recurrent or late-onset aGVHD.
Occurring more than 100 days after transplantation, often on withdrawal of immunosuppression. Absence of cGVHD features.
cGVHD
Classic cGVHD.
Manifestations of cGVHD without features of aGVHD.
Overlap syndrome.
Simultaneous features of both cGVHD and aGVHD at any time. cGvHD, and both of these categories have higher QoL than patients with severe cGVHD. 63 Patients with overlap subtype of cGvHD report worse QoL and higher symptom burden than patients with classic cGvHD. 15 As for age, middle-aged (41-59 years) patients report lower QoL compared wih younger (18-40 years) or older patients (⩾60 years). 70 Importantly, patients affected by cGvHD have significant impairment in QoL compared with age-and sex-matched US population normative data. 65 Although there is some controversy on how does tissue-specific affectation impact QoL, the presence of sclerotic, skin, joints-fascia, and/or lung involvement is thought to have the greatest deteriorating effect on the QoL of moderate-severely affected cGvHD patients. 53 Other important determinants of patient-reported QoL might be gastrointestinal involvement and elevated bilirubin, 71 or skin and nutrition symptoms in patients with overlap syndrome. 15 More specifically, the physical domain of QoL warrants special attention since both allo-HSCT and GvHD, acute or chronic, are known to impair physical functioning, 1, 50, 53, 61, [72] [73] [74] [75] [76] limiting a patient's ability to carry out daily living activities. 1, 59, 61 Long periods of bed rest or use of a wheel chair lead to muscle atrophy and cachexia, reducing functional capacity, 1, 77 and the adverse effects of immunosuppressive therapy (that is, osteoporosis, osteonecrosis, diabetes mellitus, hypertension, problems in a growing child) further limit a patient's physical capacity, increasing patient morbidity. 1, 50, 59, 61, 63 The clinical severity of cGvHD is associated with the magnitude of functional deterioration, 15, 53, 61, 65 especially in older patients, in whom the decline is more marked compared with their younger peers. 70 Besides aging, 65 other independent predictors of physical impairment in cGvHD are intensive systemic immunosuppression, reduced capacity for ambulation and greater cGvHD symptom bother. 61 Other important contributors to the decline in patients' physical functioning are upper gastrointestinal and overall liver involvement. 71 Patients with overlap syndrome are thought to suffer more marked functional impairment compared with those with classic cGvHD. 15 Accordingly, patient-reported QoL and physical functioning are considered important end points of clinical trials. 64 These end points need to be measured using reliable, safe, practical, valid methods with the objectives of: (i) quantifying the effects produced by cGvHD on physical fitness; (ii) monitoring changes produced over time in these end points in response to an intervention targeted at modifying lifestyle habits; and (iv) establishing a common vocabulary for the clinicians managing and caring for these patients. Currently, several assessment tools are available for the different aspects of the Figure 2 . Clinical manifestations of chronic GvHD and how they affect patients' daily physical function and quality of life (QoL).
Exercise for patients with cGVHD C Fiuza-Luces et al The LFS is calculated from the FEV 1 and DLCO corrected for hemoglobin. The FEV 1 and DLCO are converted to a numeric score as follows: 480 = 1; 70-79% = 2; 60-69% = 3; 50-59% = 4; 40-49% = 5 and o40% = 6. The LFS = FEV 1 score+DLCO score, with a possible range of 2-12, with higher numbers indicating worse dysfunction. The LFS (0-3) is derived as follows: 0 = FEV 1 480% or LFS 2; 1 = FEV 1 60-79% or LFS 3-5; 2 = FEV 1 40-59% or LFS 6-9 and 3 = FEV 1 o39% or LFS 10-12.
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Portable spirometry serves to record of FEV 1 after the patient is instructed to take a deep breath and exhale forcefully and rapidly (three measures), although formal pulmonary function testing is preferable if available.
Respiratory capacity. Lung capacity ROM Using a standard goniometer in the supine position, participants' mean bilateral ROM measurements are converted to the percentage of normal ROM, using the American Academy of Orthopedic Surgeons' definition of normal ROM for each joint: measurements that exceeded the maximum value are assigned a score of 100 and joints with fixed contractures are assigned a score of 0, and an aggregate score 125 is calculated representing the patient's average degree of impairment in upper and lower body ROM.
Joint/fascia response
It is a series of images that captures ROM separately for shoulders, elbows, wrists/fingers and ankles, 83 with lower scores indicating more limited ROM. The P-ROM total score is the sum of scores in all four joints, with a maximum possible score of 25.
Joint/fascia response. ROM B HAP It is a 94-item self-reported assessment of energy expenditure and physical fitness.
Responders are asked to indicate, whether they are 'still doing this activity' , 'have stopped doing this activity' , or 'never did this activity' . Two scores are calculated: the MAS, which is the number of the most difficult task the respondent is 'still doing' , and the AAS, calculated by counting how many activities with lower values than the MAS the respondent has 'stopped doing' and subtracting this from the MAS.
Daily activity. Physical functioning
SF-36
This tool is a 36-item self-report questionnaire that examines following domains: physical functioning, role limitations as a result of physical functioning, bodily pain, general health, vitality, social functioning, role emotional functioning, and mental health. These domains can be aggregated into two summary scales: the PCS and the MCS, both of them are derived by using a standard algorithm to aggregate scores across the eight domains (population mean of 50; SD of 10). SF-36 higher scores indicate better functioning; lower scores on the PCS indicate limitations in physical functioning and role participation, a high degree of bodily pain, and an unfavorable perception of general health.
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QoL. Functional health and wellbeing FACT-BMT It is a 37-item self-report questionnaire that measures the effect of cancer therapy on domains including physical, functional, social/family, and emotional well-being, and bone marrow transplantation concerns. Individual domain scores can be summarized to give a total FACT-BMT score (including all subscales) or a FACT-TOI (physical well-being +functional well-being+BMT subscale).
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QoL L-cGvHD-SC It is 30-item, 7-subscale symptom scale self-administered patient that evaluates adverse effects of cGvHD on skin, vitality (energy), lung, nutritional status, psychological functioning, muscles and joints, eyes and mouth. A summary score is created by taking the mean of all items and linearly transforming that value to a 0-100 scale. 79 We can find a muscle/ joint subscale which is a summary of four items, i.e., joint and muscle aches, limited joint movement, muscle cramps and weak muscles, with each item rated as follows: 0 → not at all; 1 → slightly; 2 → moderately; 3 → quite a bit; 4 → extremely.
It uses a 0-3-point scale. 0: no symptoms; 1: mild tightness of arms or legs, normal or mild decreased ROM and not affecting ADL; 2: tightness of arms or legs or joint contractures, erythema thought due to fasciitis, moderate decrease in ROM and mild-to-moderate limitation of ADL; 3: contracture with significant decrease of ROM and significant limitation of ADL (unable to tie shoes, button shirts, dress self, etc). Exercise for patients with cGVHD C Fiuza-Luces et al ⩾ 70% of the patients in each study cohort having cGvHD and being predominantly adults. Definitions: progressive onset of chronic GvHD is that following unresolved acute GvHD, quiescent onset of cGvHD is that occurring after complete resolution of acute GvHD, and de novo onset of cGvHD is that appearing in patients who have not had previous acute GvHD.
a Characteristics of the patients grouped by presence or absence of joint/fascia manifestations at the time of enrollment.
Exercise for patients with cGVHD C Fiuza-Luces et al physical QoL domain of the patient with cGvHD (see Table 2 for a detailed description of these tests). Many of these tests are recommended by the NIH Consensus Conference on cGvHD. 12, 78, 79 The reader is referred to Table 3 for a detailed analysis of the studies that have used these tests on patients with cGvHD.
Functional capacity tests The 2-minute walk test (2MWT) 80 has been used to assess a dimension of the therapeutic response in patients with cGvHD. 12 In patients with cGvHD, an abnormal 2MWT result has been associated with a higher symptom burden, impaired QoL, functional disability, increased mortality 81 and NIH global severity score. 53 To assess arm strength as an indicator of muscle mass and the nutritional state of the patient, the hand grip strength (HGS) test has proved useful. 82 However, despite significant correlation detected between NIH global severity and hand grip strength test scores, 81 NIH do not support its use. 53 To assess respiratory capacity, the NIH lung scoring system has two parts: a clinical lung symptom score based on symptoms and the lung function score (LFS), which is used when pulmonary function tests are available. 9 As a useful measure of joint response, the NIH consensus group recommend active-assisted upper and lower body range of motion (ROM). 12 NIH global severity scores show significant correlation with ROM. 53 However, the need for a trained clinician to conduct ROM measurements is a major limitation of this technique. 12 As an objective and simple alternative, the photographic-ROM (P-ROM) scale was developed 83, 84 to assess joint/fascia manifestations in patients with cGvHD. In addition, the NIH joint/fascia scale was designed to evaluate the severity of GvHD manifestations in joints and fascia for baseline or crosssectional use, 9 though this test could also be used to assess the response to a treatment intervention. 84 The reduced functional capacity of patients with cGvHD has been confirmed by measurements made in the tests 2MWT, 15 84 Such functional decline is more marked in patients ⩾ 60 years 70 or with overlap syndrome (as indicated by a longer 2MWT in both cases). 15 Patients with moderate-to-severe cGvHD requiring moderate-tohigh levels of immunosuppression experience significant functional limitations, 61 although the findings of some studies suggest no detrimental effects on QoL of immunosuppressive therapy. 63, 88 Patient's self-reports of functional capacity and physical domain of QoL The human activity profile (HAP) is a self-reported assessment tool in which activities are rated according to the energy expenditure required to perform a specific task. 12, 50, 89 This questionnaire has proved more sensitive to changes in cGvHD status and to the presence of toxicity than other self-reported assessment methods (such as the Medical Outcomes Study 36-Item ShortForm Health Survey (SF-36), and the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)). 50 Hence, it may be of use to measure the impacts of severity of cGvHD and side effects of immunosuppression on physical functioning, and the response to cGvHD therapy in clinical trials. 50 Moreover, HAP shows a high internal consistency with cGvHD severity. 50 The SF-36, v.2, assesses patient-reported functional health, functioning and well-being. 90 The use of a norm-based scoring system helps interpret SF-36 scores such that any score below 50 is below the US population mean, and each point represents one-tenth of an SD, with this scale allowing to assess some dimensions of the response to cGvHD treatment. 12, 90 The FACT-BMT v4.0 questionnaire includes a 10-item Bone Marrow Transplant Subscale (BMTS). 91 No significant differences between SF-36 and FACT-BMT in discriminating cGvHD severity have been detected, particularly in the physical domains. 65 However, the FACT-General core survey has been recommended over SF-36 and the FACT-BMTS subscale since the core survey substantially reduces respondent burden without compromising multi-dimensional QoL comprehension or the tool's sensitivity to change. 66 The Lee cGvHD Symptom Scale (L-cGvHD-SC) evaluates several symptoms of cGvHD 79 and may be effective to monitor these dimensions of the response to cGvHD therapy. 12 Chronic GvHD-affected individuals show modified SF-36 physical component scores (PCS) 61, 66 and those with severe cGvHD show a reduced SF-36 mental component score. 66 In patients older than 60 years compared with those younger than this age, HAP scores are lower, though QoL (FACT-BMT) is improved over that observed in patients aging from 41 to 59 years. 70 Further, patients with acute/chronic GvHD overlap syndrome return worse HAP and social functioning scores (SF-36) than patients with classic cGvHD. 15 NIH global severity scores have been correlated with scores obtained in L-cGvHD-SC, FACT-BMT, HAP and SF-36 PCS, with the exception of the mental component of the SF-36 score. 53 Those with moderate-to-severe cGvHD show similar SF-36 PCS scores to those reported for patients with immune-mediated disorders, yet these scores are lower than those observed in patients with common chronic medical conditions. 65 
RATIONALE FOR EXERCISE INTERVENTIONS IN PATIENTS WITH CGVHD: WHAT CAN WE LEARN FROM RESEARCH IN OTHER CHRONIC CONDITIONS
Given the serious consequences of cGvHD and the secondary effects of conditioning regimens, allo-HSCT and drug treatments, new approaches to the care of patients with cGvHD are urgently needed. There is strong scientific evidence to support the therapeutic benefits of non-pharmacological interventions such as regular physical exercise (see Fiuza-Luces et al. 8 for a review of the main therapeutic and preventive benefits of exercises and some of the molecular mechanisms involved)). This lifestyle intervention is an effective coadjuvant treatment against several chronic diseases, especially those in which an inflammatory state is produced (for example, cancer). Its benefits include an improved cardiorespiratory capacity, measured as peak oxygen uptake, VO 2 peak. The latter is one of the variables that best responds to physical exercise, and is also a strong prognostic factor of mortality attributable to chronic disease. Further benefits include improved functional and muscular capacity, diminished systemic inflammation and improved immune function, reducing some of the side-effects of cancer treatment such as fatigue. 8 Despite such benefits, however, at present there is no scientific evidence of the effects of exercise in patients with cGvHD. So far, physical exercise interventions have targeted patients subjected to allo-HSCT though some programs have included patients with GvHD. 92 Unfortunately, none of the studies assessing the effects of exercise on allo-HSCT recipients has analyzed separately the subset of patients suffering this condition, and in fact the authors did not even make a distinction between aGvHD and cGvHD [see 92 for a review]. Keeping these limitations in mind, among the positive exercise impacts on QoL are improved endurance/aerobic capacity, muscular strength, functional capacity, perceptions of fatigue, physical emotional and social well-being, and reductions in perceived pain scores and subdued anxiety, depression and aggressive or hostile behavior. 92 Although patient cohorts and experimental designs in these studies are very heterogeneous, it seems likely that both aerobic-and resistance based exercise appears to positively impact QoL in GvHD patients.
PRECLINICAL EXERCISE INTERVENTION STUDIES IN CGVHD
Owing to the lack of exercise interventional research in patients, our research group decided to conduct preliminary, preclinical studies. Thus, we examined the effects of exercise in an experimental scleroderma [B10.D2 (H-2 d ) → BALB/C (H-2 d )] mouse model of cGvHD. In a first study, we showed that the functional capacity (determined as maximal running velocity attained during a gradual treadmill test until exhaustion) of mice with cGvHD and receiving no drug treatment inevitably declined 12 weeks after allo-HSCT (with donor bone marrow cells and splenocytes), which was preceded by myeloablative irradiation. Yet compared with the control group, such decline was significantly less marked in those mice that had followed a moderate-intensity aerobic treadmill running program (five sessions/week, Monday to Friday) that started shortly (2 days) after allo-HSCT and was prolonged until 11 weeks post transplant. The training program mimicked the widely accepted public health recommendations for physical activity in humans, that is, accumulating 30+ min of such type of moderate-intensity exercise (for example, brisk walking, jogging) in most (if not all) days of the week. 93 The cGvHD has catabolic effects at the muscle tissue level and also leads to homeostatic and hormonal alterations. 92 Despite such disease effects, the trained mice showed higher activity of the musculoskeletal enzyme citrate synthase, a key marker of oxidative capacity and mitochondrial biogenesis. Thus, we propose that a shift towards a more 'oxidative' muscle phenotype could have positive repercussions on health and resistance to certain diseases. 93 In fact, classic studies in rats by Koch and Britton's group showed that improved oxidative pathways in mitochondria may be a common factor linking physical fitness and decreased disease risk. 94, 95 Further, exercise training did not negatively affect the kinetics of immune reconstitution in the context of severely debilitated and immunocompromised mice receiving lethal irradiation and transplantation. 93 This finding suggests that the exercise would not negatively affect the graft-versus-tumor or the graft-versusinfection effect of the transplant. Further experiments using models adapted for these two situations (that is, tumor or infectious agents) will elucidate these clinically important questions. Although the beneficial effects of moderate-intensity exercise on the immune function of healthy individuals are well documented, 96 there is more controversy regarding its effects in immunocompromised people 97 and our results in mice with cGvHD are in line with previous findings showing no benefit but also no harm on immune reconstitution in patients with hematological cancer. 98, 99 Also noted in this first study, were reduced IL6 levels. 93 Thus, our preliminary findings suggest that exercise might attenuate the severe physical decline (and thus benefit the physical domain of QoL) in debilitated and immunocompromised patients, such as those suffering cGvHD.
In a second study, 100 we examined the effects of the same type of exercise training in the same cGvHD model, which received a standard immunosuppressive treatment for this disease, that is, cyclosporine-A. Immunosuppressant drugs induce severe side effects at the multisystem level including muscle tissue deterioration, 101, 102 with some human studies suggesting a link between cyclosporine-A and myopathies associated with heart or liver transplant or with the treatment against Graves disease.
103 In animal models, chronic administration of cyclosporine-A reduces physical capacity, and the magnitude of the decline is linked to the extent of mitochondrial alteration. 104 Importantly, the results of our second study suggested beneficial effects on survival, the clinical course of cGvHD and on physical capacity in the exercise group, compared with the control group. 100 Further, the exercise intervention had a favorable effect on different immune cell compartment kinetics, led to a less aggressive inflammatory profile, and offset the toxic effects of the immunosuppressive treatment. 100 Specifically, the scleroderma cGvHD mouse model that we used is dependent on CD4 + cells, which activate Th2 lymphocytes secreting IL2, IL5, IL9, IL10, IL13 and TNFα. Growing levels of these cytokines are linked to disease progression. 105, 106 Our exercise program led to lower levels of TNFα and IL4 after 12 weeks post transplant compared with the control group. 100 Further research is needed to determine the mechanisms explaining such exercise effects on cytokine profile. On the other hand, patients with cGvHD have reduced levels of B-and CD4 + T-helper cells 29 which, together with the altered lymphopoiesis and the drug effects, result in long-lasting immunodeficiency. 107 Thus, the finding that the treatment program did not negatively affect immune reconstitution, and in fact tended to favor it, at least partly (that is, we found higher blood levels of B220 and CD4 + cells in the exercise group at 21 days post-allo-HSCT), has potential clinical relevance. 100 In this regard, Ko et al. 108 showed an improvement in the immune function of healthy mice treated with cyclosporine-A that followed an 8-week moderate-intensity treadmill training compared with those receiving the drug but not performing the training, suggesting a beneficial immunomodulatory effect of exercise that is yet to be corroborated in humans receiving the dame drug.
In a final study, physical exercise promoted the induction of myocardial autophagy in trained mice surviving 12 weeks following allo-HSCT, suggesting this could be one of the biological mechanisms mediating the beneficial effects of exercise in cGvHD in the later stages of life. 109 Indeed, autophagy, a catabolic route of degradation and recycling of cellular components in all tissues, is an important cardioprotective mechanism that helps to 'declutter' the cell and restore its functionality, including in pathological and aging conditions, with suppression of genes involved in autophagy leading to altered cardiac function. [110] [111] [112] Several studies also showed improved myocardial autophagy in trained rodents. [113] [114] [115] [116] In addition, our data also showed higher levels of antioxidant enzymes in the hearts of exercised mice. 109 Thus, both training-enhanced autophagy and myocardial antioxidant capacity might confer heart-muscle protection against radiation toxicity. In this regard, De Lisio et al. showed that exercise training enhances mouse skeletal-muscle response of antioxidant and mitochondrial enzymes to radiation. 117 
FROM PRECLINICAL STUDIES TO CLINICAL TRIALS: SUGGESTED FEASIBILITY AND POTENTIAL LIMITATIONS OF EXERCISE INTERVENTIONS IN PATIENTS WITH CGVHD
It must be kept in mind that exercise interventions targeted to attenuate the physical decline of patients with cGvHD and the impact of such decline in their daily living and QoL are likely to face numerous limitations, especially at end-stages of the disease and/or in the more severely affected individuals. Figure 2 shows the clinical aspects of the disease that are more likely to affect the exercise capacity and adherence to the program. Notably, not only the manifestations of the disease per se but also the side effects of the treatment and prolonged bed rest can further deteriorate the patients' physical condition and physical domain of QoL. The negative impact of the disease at multisystem level (cardiorespiratory, immune and gastrointestinal systems) can decrease the capacity of the patient to improve aerobic capacity and muscle anabolism in response to training interventions. Many patients have low walking capacity, or even low capacity for standing from a chair, which limits the range of exercises that can be applied. Nonetheless, our group has shown the feasibility, safety and benefits of individualized exercise interventions (often performed in the hospital setting) usually combining lowmoderate intensity aerobic and resistance (that is, weight lifting) exercises in other debilitated, fragile populations, including nursing home resident nonagenarians, 118 hospitalized octogenarians 119 (most of whom, like the nonagenarians, had very poor walking capacity and serious difficulties in coping Exercise for patients with cGVHD C Fiuza-Luces et al independently with common activities of daily living). Implementation of specific types of weight lifting training (that is, leg press at low loads or simply standing from a chair several times a day) is feasible, safe and effective even in the 'oldest old' people (90+ years) 118 or in anorexic adolescents who often suffer metabolic myopathy due to protein malnutrition. 120 Further, special 'in-room' exercise interventions (for example, including light weight lifting while lying in bed) are effective and feasible in isolated, highly immunocompromised children during inpatient hospitalization for pediatric allo-HSCT. 98 Finally, other special and simple interventions such as specific inspiratory load training to improve the function of breathing musculature with special, small size breathing devices (for example, 'power breathe') are easily applicable even in patients' homes, as we have shown in children with cystic fibrosis. 121 In the above mentioned fragile populations, besides the almost unanimous benefits in aerobic capacity or muscle strength, in some patient populations the exercise interventions also produced improvements in: (i) the individuals' ability to cope independently with daily living (for example, decreased risk of falls in nonagenarians 118 or improved performance in functional tests in children who had received allo/haploidentical HSCT); 122 or (ii) self-reported QoL, for example, improved self-report of comfort and resilience in pediatric patients who had undergone HSCT. 122 On the other hand, based on our own experience, previous research on pediatric/adult hematological cancer, 123 as well as on specific recommendations by leading institutions such as the American College of Sports Medicine 124 which state that adult cancer survivors should avoid inactivity as soon as possible after diagnosis and in fact adhere to the 2008 Physical Activity Guidelines for Americans (that is, adults should undertake ⩾ 150 min/week of moderate physical activity such as brisk walking); we recommend that patients with cGvHD also adhere to these guidelines as soon as possible after diagnosis of the disease. In fact, an active lifestyle should be ideally adopted upon diagnosis of the disease that resulted in allo-HSCT.
FUTURE DIRECTIONS
Our results reveal the potential therapeutic value of regular physical exercise in allo-HSCT recipients who suffer the devastating effects of cGvHD. Given the foreseeable increase in the number of patients who will receive a transplant from an unrelated donor in the years to come, the incidence of GvHD will also rise and this will be accompanied by increased healthcare costs. To further our understanding of cGvHD, research efforts need to focus on determining the optimal mode, intensity and volume of exercise that will lead to an improved clinical course and QoL of these patients. It will also be important to determine if exercise has a direct impact on the pathobiology of GvHD or if it can serve as an adjuvant for ATG (anti-thymocyte globulin) therapy or other pharmacological interventions aimed at dampening the severity and/or lowering the incidence of GvHD. Moreover, the timing of when the exercise intervention is delivered may also influence GvHD incidence and severity, be it before ('prehabilitation'), during or after hospitalization for allo-HSCT. To guarantee the validity, reliability and reproducibility of the data emerging from future work, variables of interest need to be measured using adequate tools by interdisciplinary teams of experts who care for patients with cGvHD.
